Amy Chadburn

Q: What Schools Are Affiliated With Amy Chadburn

Amy Chadburn is affiliated with the following schools: University of Oxford, Northwestern University, Stanford University, Cornell University, Columbia University, University of Nebraska Medical Center

Amy Chadburn's AcademicInfluence.com Rankings

Amy Chadburn

Computer Science

#8554

World Rank

#8992

Historical Rank

Computational Linguistics

#1927

World Rank

#1948

Historical Rank

Machine Learning

#3532

World Rank

#3576

Historical Rank

Artificial Intelligence

#3841

World Rank

#3897

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Amy Chadburn's Degrees

Masters Artificial Intelligence Stanford University

Similar Degrees You Can Earn

Best Online Master's in Artificial Intelligence 2026

Why Is Amy Chadburn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Amy Chadburn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth (2001) (1988)
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. (2005) (1433)
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. (1996) (1145)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma (2009) (1047)
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. (2008) (959)
Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma (2011) (929)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma (2010) (855)
Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. (2007) (710)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma (2017) (677)
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. (1996) (615)
The genetic landscape of mutations in Burkitt lymphoma (2012) (533)
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. (1995) (526)
Genetic heterogeneity of diffuse large B-cell lymphoma (2013) (488)
Genetics of follicular lymphoma transformation. (2014) (458)
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. (2000) (456)
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. (2005) (400)
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. (2017) (320)
Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. (2006) (319)
Outcome of deferred initial therapy in mantle-cell lymphoma. (2009) (318)
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. (2011) (304)
Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI (2007) (301)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022) (293)
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. (2010) (284)
KSHV-Positive Solid Lymphomas Represent an Extra-Cavitary Variant of Primary Effusion Lymphoma (2004) (280)
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. (2010) (279)
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components (2009) (275)
Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. (2003) (260)
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. (2015) (254)
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. (2003) (246)
Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. (2006) (230)
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. (2010) (229)
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. (2003) (225)
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. (2010) (223)
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. (2007) (222)
Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells (2006) (220)
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma (2004) (219)
Lymphoma B Cells Evade Apoptosis through the TNF Family Members BAFF/BLyS and APRIL1 (2004) (217)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. (2019) (198)
Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. (1997) (193)
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. (2009) (181)
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. (2018) (179)
BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma (2009) (176)
Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. (1997) (171)
MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. (2008) (169)
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype (2012) (169)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. (2005) (168)
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. (2005) (162)
BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. (1998) (161)
HIV-1 evades virus-specific IgG2 and IgA class switching by targeting systemic and intestinal B cells via long-range intercellular conduits (2009) (160)
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. (2013) (154)
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. (2008) (152)
The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. (1998) (151)
HIV-1 Envelope Triggers Polyclonal Ig Class Switch Recombination through a CD40-Independent Mechanism Involving BAFF and C-Type Lectin Receptors1 (2006) (149)
Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene (2002) (140)
The Genetic Basis of Hepatosplenic T-cell Lymphoma. (2017) (140)
CD30 (Ki‐1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus (1993) (133)
Distinct Subsets of Primary Effusion Lymphoma Can Be Identified Based on Their Cellular Gene Expression Profile and Viral Association (2005) (133)
The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant (1998) (132)
Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. (2009) (130)
Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. (2000) (127)
Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. (1992) (126)
Association of Age With SARS-CoV-2 Antibody Response (2021) (120)
Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy (2010) (117)
High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. (1993) (116)
Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2 (2017) (116)
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders (1995) (114)
Molecular pathology of posttransplantation lymphoproliferative disorders. (1997) (112)
De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. (1995) (112)
Lymphoma B Cells Evade Apoptosis through the TNF Family Members BAFF/BLyS and APRIL. (2004) (111)
Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience (2020) (106)
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. (2008) (100)
Germinal Center B Cells Regulate Their Capability to Present Antigen by Modulation of HLA-DO (2002) (96)
Anaplastic large cell lymphoma arising in a silicone breast implant capsule: a case report and review of the literature. (2009) (89)
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. (2004) (87)
Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. (1999) (87)
Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non–Hodgkin's Lymphoma (2006) (86)
Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. (2002) (84)
Molecular characterization of primary mediastinal B cell lymphoma. (1996) (84)
CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. (1996) (81)
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. (2009) (81)
Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV‐8)‐infected B cells in HIV+ multicentric Castleman disease (MCD) (2008) (80)
Posttransplantation lymphoproliferative disorders treated with cyclophosphamide‐doxorubicin‐vincristine‐prednisone chemotherapy (1993) (80)
Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. (1999) (79)
Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. (1994) (78)
Kaposi's sarcoma‐associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus (1997) (78)
The spleen: anatomy and anatomical function. (2000) (76)
Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. (1995) (76)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. (2008) (75)
Routine laboratory blood tests predict SARS-CoV-2 infection using machine learning (2020) (71)
Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. (2010) (66)
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4 (2000) (65)
Erdheim-Chester disease of the central nervous system. Report of two cases. (1997) (63)
EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report—Part 1 (2017) (62)
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. (2013) (61)
Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? (2018) (61)
Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. (1998) (60)
Epstein-Barr Virus Latent Gene Expression in Primary Effusion Lymphomas Containing Kaposi ’ s Sarcoma – Associated Herpesvirus / Human Herpesvirus - (1997) (60)
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. (2020) (59)
HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report—Part 3 (2017) (59)
Human Immunodeficiency Virus (HIV)-Associated Polymorphic Lymphoproliferative Disorders (2003) (59)
Progressive lymph node histology and its prognostic value in patients with acquired immunodeficiency syndrome and AIDS-related complex. (1989) (58)
Management of lymphoproliferative disorders after cardiac transplantation. (1993) (57)
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib (2008) (57)
Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration (2010) (57)
The tumor virus landscape of AIDS-related lymphomas. (2015) (56)
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma (2017) (55)
Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation. (1994) (50)
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. (2010) (50)
Novel association of haemophagocytic syndrome with Kaposi's sarcoma‐associated herpesvirus‐related primary effusion lymphoma (2000) (46)
Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms (1995) (46)
Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. (2006) (45)
Lymphoid proliferations associated with human immunodeficiency virus infection. (2013) (44)
BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. (2001) (43)
SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays (2020) (42)
Telomerase activity in B‐cell non‐Hodgkin lymphoma (2000) (42)
CD44 Loss in Gastric Stromal Tumors as a Prognostic Marker (2004) (42)
Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas (2010) (40)
Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia. (2011) (39)
Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results. (2005) (39)
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. (2003) (39)
Mesenchymal chondrosarcoma of the orbit. Report of three new cases and review of the literature (1994) (38)
B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report—Part 2 (2017) (37)
The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells. (1992) (37)
Improving outcomes for patients with Burkitt lymphoma and HIV. (2008) (35)
Patients with Epstein Barr virus‐positive lymphomas have decreased CD4+ T‐cell responses to the viral nuclear antigen 1 (2008) (33)
ROR1 targeting with the antibody drug-conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. (2021) (33)
Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. (2007) (32)
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate (2020) (32)
The bcl-2 gene translocation is undetectable in Hodgkin's disease by Southern blot hybridization and polymerase chain reaction. (1992) (32)
Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV (2004) (31)
Detection and characterization of human T-cell lymphotropic virus type I (HTLV-I) associated T-cell neoplasms in an HTLV-I nonendemic region by polymerase chain reaction. (1991) (30)
Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. (1997) (30)
Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. (2011) (28)
Intracerebral hodgkin's disease in a human immunodeficiency virus‐seropositive patient (1991) (28)
A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma. (2011) (27)
Down-regulation and desensitization of the beta-adrenergic receptor system of human lymphocytes after cardiac surgery. (1993) (27)
A peptomimetic inhibitor of BCL 6 with potent antilymphoma effects in vitro and in vivo (2009) (26)
Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial). (2020) (26)
KSHV induces immunoglobulin rearrangements in mature B lymphocytes (2018) (26)
Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B- or T-cell lineage of 95% of diffuse aggressive non-Hodgkin's lymphomas. (1994) (26)
Intracranial Nasal Natural Killer/T-cell Lymphoma: Immunopathologically-Confirmed Case and Review of Literature (2005) (25)
KSHV/HHV8-mediated hematologic diseases. (2021) (23)
Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. (2018) (23)
CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL) (2007) (22)
Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium (2016) (22)
Alterations of the beta-adrenergic receptor system after thoracic and abdominal surgery. (1994) (21)
Evaluation of JAK2V617F in B and T Cell Neoplasms: Identification of JAK2V617F Mutation of Undetermined Significance (JMUS) in the Bone Marrow of Three Individuals (2007) (21)
T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report—Part 4 (2017) (21)
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia. (2013) (20)
The mechanisms underlying MMR deficiency in immunodeficiency‐related non‐Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms (2009) (20)
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health (2021) (20)
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease (2019) (19)
Mutational analysis of PRDM 1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas (2006) (19)
HIV-related primary non-Hodgkin's lymphoma of the vulva. (1996) (18)
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. (2009) (18)
Eosinophilic Variant of Chronic Myeloid Leukemia with Vascular Complications (2003) (17)
Kaposi sarcoma-associated herpesvirus in non-Hodgkin lymphoma and reactive lymphadenopathy in Uganda. (2007) (17)
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS malignancies consortium clinical trials 010 and 034 (2009) (17)
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease (2020) (16)
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma (2008) (16)
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder (2020) (16)
Role of Defective Oct-2 and OCA-B Expression in Immunoglobulin Production and Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivation in Primary Effusion Lymphoma (2009) (16)
The stromal composition of mast cell aggregates in systemic mastocytosis (2009) (15)
Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals (2021) (14)
Phenotypic and functional characterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma. (1994) (14)
Bone marrow involvement by subcutaneous Panniculitis-like T-cell lymphoma: a report of three cases (2014) (14)
Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma (2009) (14)
Synergistic efficacy of dual PI3K-d/g inhibitor Duvelisib with Bcl2 inhibitor Venetoclax in Richter's Syndrome PDX models. (2021) (13)
Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis (2020) (13)
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients (2021) (13)
Peripheral eosinophilia in primary immunodeficiencies of actin dysregulation: A case series of Wiskott-Aldrich syndrome, CARMIL2 and DOCK8 deficiency and review of the literature. (2019) (12)
Mediastinal large B-cell lymphoma vs classic Hodgkin lymphoma. (1999) (12)
Spleen: Development, anatomy and reactive lymphoid proliferations. (2020) (12)
Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma (2008) (11)
Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report—Part 5 (2017) (11)
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement (2007) (11)
COVID-19 Viral and Serology Testing in New York City Health Care Workers (2020) (11)
TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability (2021) (11)
Phase 1/2 trial of BMS‐275291 in patients with human immunodeficiency virus‐related Kaposi sarcoma (2008) (11)
Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) (2004) (10)
AIDS-Related Lymphomas (2010) (10)
Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL). (2004) (10)
Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. (2017) (10)
T-cell activation-associated antigen expression by neoplastic T-cells. (1992) (10)
Hairy cell leukemia-associated antigen LeuM5 (CD11c) is preferentially expressed by benign activated and neoplastic CD8 T cells. (1990) (9)
KSHV LANA inhibits TGF- (cid:1) signaling through epigenetic silencing of the TGF- (cid:1) type II receptor (2008) (9)
Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS) (2019) (9)
Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up (2021) (9)
Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease. (2006) (9)
Monoclonal antibody OPD4 detects neoplastic T cells but does not distinguish between CD4 and CD8 neoplastic T cells in paraffin tissue sections. (1992) (8)
Splenic cord capillary hemangioma and anemia: Resolution after splenectomy (2006) (8)
Leptomeningeal Involvement in a Patient with Splenic Lymphoma with Villous Lymphocytes (2002) (8)
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients (2020) (8)
Epigenetic Memory of COVID-19 in Innate Immune Cells and Their Progenitors (2022) (8)
NK/T cell non-Hodgkin lymphoma in a HIV-positive patient (2010) (7)
Molecular and immunohistochemical detection of Kaposi sarcoma herpesvirus/human herpesvirus-8. (2013) (7)
A novel murine model of Cooley’s anemia and its rescue by lentiviral mediated human ß-globin gene transfer (2002) (7)
DNA polymerase mu gene expression in B-cell non-Hodgkin's lymphomas: an analysis utilizing in situ hybridization. (2002) (7)
Immunodeficiency-associated lymphoid proliferations (ALPS, HIV, and KSHV/HHV8). (2013) (7)
Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract (2019) (7)
Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC) (2013) (7)
Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. (2016) (7)
Intensive Treatment Strategies May Not Provide Superior Outcomes in Mantle Cell Lymphoma: Overall Survival Exceeding Seven Years in a Large Cohort of Patients Managed Primarily with Conservative Therapies. (2007) (7)
American Registry of Pathology expert opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. (2020) (6)
Reply to K. Dunleavy et al (2010) (6)
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV- associated, B-cell non-Hodgkin's lymphoma. (2020) (6)
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. (2020) (6)
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085 (2019) (6)
Lack of A563G (I188V) missense mutation in RIZ/ PRDM2 in human diffuse large B‐cell lymphomas (2007) (6)
gene-globin β human-thalassemia intermedia by transfer of the β Successful treatment of murine (2002) (6)
1 Decreased Differentiation of Erythroid Cells Exacerbates Ineffective Erythropoiesis in β -Thalassemia (2008) (6)
The TNF Family Members BAFF and APRIL Play an Important Role in Hodgkin Lymphoma. (2005) (6)
associated with the Kaposi's sarcoma-associated herpes virus Primary effusion lymphoma: a distinct clinicopathologic entity (2011) (5)
TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability (2021) (5)
Assessment of the Utility of Cytology and Flow Cytometry of Cerebrospinal Fluid Samples in Clinical Practice (2018) (5)
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data* (2018) (5)
Lymph node biopsy in patients with human immunodeficiency virus infections. (1988) (5)
Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome. (2008) (5)
CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL). (2009) (5)
Structural and Functional Analysis of Oncogenes and Tumor Suppressor Genes in Adult T-cell Leukemia / Lymphoma Shows Frequent p 53 Mutations (2003) (4)
Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma (2019) (4)
Lymphoid malignancies: immunophenotypic analysis. (2003) (4)
Corrigendum: Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells (2016) (4)
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML (2021) (4)
MicroRNA-Mediated Translation Repression of PRDM1 in Hodgkin/Reed-Sternberg Cells - A Potential Pathogenetic Lesion in Hodgkin Lymphoma. (2006) (4)
Synchronous multiple myeloma and Gaucher disease. (2020) (3)
Machine learning analysis highlights the down-trending of the proportion of COVID-19 patients with a distinct laboratory result profile (2020) (3)
CD79b Expression in Richter's Transformation (2019) (3)
BTG1 mutation yields supercompetitive B cells primed for malignant transformation (2023) (3)
Morphologic , Immunophenotypic , and Molecular Cytogenetic Assessment of CD 4 – / CD 8 – γδ T-Cell Large Granular Lymphocytic Leukemia (2011) (3)
An angiocentric orbital lesion with an immature natural killer cell immunophenotype. (2001) (3)
Lymphoproliferations of Immunodeficiency (2007) (3)
Megakaryocytes in bronchial brush cytology. A case report. (1993) (3)
The genetic landscape of immune-competent and HIV lymphoma (2012) (3)
Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy. (2017) (3)
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study (2008) (2)
AIDS-RELATED POLYMORPHIC LYMPHOPROLIFERATIVE DISORDERS.: 116A (1997) (2)
Anaplastic Large Cell Lymphoma Arising in a Silicone Breast Implant Capsule (2)
SETD2 haploinsufficiency enhances germinal center-associated AICDA somatic hypermutation to drive B cell lymphomagenesis. (2022) (2)
Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study (2020) (2)
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy (2022) (2)
A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes (2019) (2)
Inactivation Of BANK1 By a Novel IGH -Associated Translocation and 5’ Hypermethylation In B-Cell Lymphomas (2013) (2)
Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain (2019) (2)
Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. (2019) (2)
Blastic plasmacytoid dendritic cell neoplasm: Report of a case with extracutaneous presentation and extensive bone marrow involvement (2012) (2)
Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401) (2015) (2)
More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals (2021) (2)
C{micro}->C{delta} Class Switch Recombination and IgD Production Contribute to Mucosal Immunity (2008) (2)
Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML). (2006) (2)
Pathology of B-cell non-Hodgkin's lymphomas and multiple myeloma. (2006) (2)
Epithelial cells trigger frontline immunoglobulin class switching through an SLPI-regulated pathway (41.7) (2007) (2)
Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues (2011) (2)
The Influence Of Lifestyle Factors On Tumor-Related Markers and The Microenvironment In Follicular Lymphoma (FL): Novel Interactions and Collective Impact On Survival (2013) (2)
Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma (2011) (2)
Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses (2017) (2)
TNFAIP3 (A20) Genetic Alterations In EBV Associated AIDS Related Lymphomas (2010) (1)
Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2020) (1)
Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma (2010) (1)
Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity (2021) (1)
FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma. (2005) (1)
CORRELATIVE MORPHOLOGIC AND MOLECULAR GENETIC ANALYSIS OF 75 AIDS-RELATED SYSTEMIC NON-HODGKIN LYMPHOMAS: 136 (1997) (1)
EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort (2020) (1)
Generation of vFLIP Transgenic Mice: A Model to Study KSHV-Associated Lymphomagenesis (2008) (1)
Scavenger Receptor Type B1 Is Essential for High Density Lipoprotein Nanoparticle Induced B-Cell Lymphoma Cell Death (2015) (1)
Splenic Sinusoids Stimulate the Survival and Proliferation of Hairy Cell Leukemia B Cells through BAFF, APRIL and Heparan-Sulphate Proteoglycans. (2006) (1)
Castleman disease spectrum. (2020) (1)
Forward for Aggressive B-cell Lymphomas: Selected Entities (2012) (1)
Malignant B Cells from Hairy Cell Leukemia Express an Innate Phenotype and Undergo IgD Class Switching in Response to Innate Environmental Factors, Including BAFF and APRIL. (2007) (1)
Stromal Incorporation of VEGFR-1+, CD68+ and α-SMA+ Hemangiogenic Cells Correlates with Histologic Subtype in Non-Hodgkin’s Lymphoma. (2005) (1)
Machine Learning Highlights Downtrending of COVID-19 Patients with a Distinct Laboratory Profile (2021) (1)
Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes. (2006) (1)
Neither Germinal Center (GC) vs Non-Germinal Center (Non-GC) Phenotype nor FOXP1 Expression Correlate with Outcome in AIDS-Associated Diffuse Large B-Cell Lymphoma (DLBCL): Study of Patients from AIDS Malignancies Consortium Trials 010 and 034. (2006) (1)
HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL (2017) (1)
Intestinal Bacteria Induce T Cell-Independent IgA2 Class Switching by Linking Epithelial Cells with Lamina Propria B Cells through APRIL (40.3) (2007) (1)
APRIL generate survival and proliferation signals in response to BAFF and Hodgkin lymphoma cells express TACI and BCMA receptors and (2013) (1)
The Risk of Hepatosplenic T-Cell Lymphoma (HSTCL) in Women with Inflammatory Bowel Disease (IBD) on Thiopurines (2016) (1)
Limited Tissue Samples: Hematopoietic Lesions – Three Case Examples of Judicious Use of Limited Material (2019) (1)
Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site (2022) (1)
Gene expression profiling using formalin-fixed paraffin-embedded primary specimens of AIDS-related Lymphomas (2012) (1)
Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma (2014) (1)
ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis (2021) (1)
Chapter 4 B-cell and classical Hodgkin lymphomas associated with immunodeficiency (2017) (1)
Activation of Classical and Alternative Nuclear Factor-kappaB (NF-kB) Pathways in Diffuse Large B-Cell Lymphomas. (2004) (1)
The Landscape of microRNA Expression in HIV and Non-HIV Associated Classical Hodgkin Lymphoma through Next Generation Sequencing (2015) (0)
Abstract 3887: Reversible inhibition of CDK4/CDK6 sensitizes hematological tumor cells for cytotoxic killing by inducing sequential G1 arrest and synchronous S phase entry that enhances the intrinsic apoptosis pathway (2010) (0)
Microenvironment Assessment, Disease Characteristics and Prognosis In HIV-Associated (HIV-cHL) and HIV-Negative Classical Hodgkin Lymphoma: The Influence Of Epstein Barr Virus (EBV) (2013) (0)
Phenotypic and Functional Characterization of T-BAM ( CD 40 Ligand ) ’ T-cell Non-Hodgkin ’ s Lymphoma (2000) (0)
AGGRESSIVE B-CELL LYMPHOMAS ASSOCIATED WITH IM- MUNOSUPPRESSION DIFFUSE LARGE B-CELL LYMPHOMA: MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL CORRELATIONS LYMPHOMA: NEW INSIGHTS INTO MOLECULAR HETEROGE-NEITY AND RATIONAL TREATMENT TARGETS (2003) (0)
HIV-1 Nef Suppresses T Cell-Dependent Immunoglobulin Class Switching by Inducing Inhibitors of CD40 and IL-4 Receptor Signaling in Bystander B Cells. (2005) (0)
Targeting Scavenger Receptor Type B1 In Cholesterol-Addicted Lymphomas Abolishes Glutathione Peroxidase 4 and Results in Ferroptosis (2020) (0)
Classification of Lymphomas (2011) (0)
Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome (2022) (0)
Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma (2013) (0)
Cμ→Cδ Class Switch Recombination and IgD Production Contribute to Mucosal Immunity (2008) (0)
B Cells & Lymphoid Organogenesis (2009) (0)
BAFF and C-Type Lectin Receptors CD 40-Independent Mechanism Involving Switch Recombination through a HIV-1 Envelope Triggers Polyclonal Ig Class (2006) (0)
Alterations of the P-Adrenergic Receptor System After Thoracic and Abdominal Surgery (2006) (0)
Immunosuppression and lymphomagenesis (2009) (0)
Hemoglobin C after a red blood cell transfusion for sickle cell disease (2015) (0)
Primary Mediastinal B-Cell Lymphoma in Children and Young Adults. (2023) (0)
Immune Microenvironment in PTLDs: Comparison With Outcome and Other EBV+ Lymphoproliferative Disorders in Immunocompetenet and Immunodeficient Individuals (2012) (0)
Lack of PRDM1α Expression in Hodgkin/Reed-Sternberg Cells Is Likely Mediated by a Translational or Post-Translational Mechanism. (2005) (0)
110 Nef-Trafficking Intercellular Highways for HIV Evasion of Antibody Production: (2011) (0)
BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells (2021) (0)
Transferrin receptor expression in testis cancer. (1994) (0)
The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas (2021) (0)
Metagenomic analysis to identify novel infectious agents in systemic anaplastic large cell lymphoma (2021) (0)
T- cell non-Hodgkin's lymphoma Phenotypic and functional characterization of T-BAM (CD40 ligand)+ (2011) (0)
MYC and BCL2 Gene Rearrangements in Comparison to MYC and BCL2 Protein Expression in AIDS-Related Diffuse Large B Cell Lymphomas (2016) (0)
Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. (2020) (0)
of ferroportin up-regulation iron absorption mediated by down-regulation of hepcidin and -thalassemia is characterized by increased β Ineffective erythropoiesis in (2013) (0)
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. (2023) (0)
Gene expression profiling using formalin-fixed paraffin-embedded primary specimens of AIDS-related Lymphomas (2012) (0)
Contents Vol. 118, 2007 (2007) (0)
Endobronchial Obstruction by a Solitary Extramedullary Plasmacytoma With Light-chain Amyloidosis. (2019) (0)
Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma (2021) (0)
Bone Marrow Involvement by Subcutaneous Panniculitis-like T-Cell Lymphoma: A Report of 3 Cases (2012) (0)
EXPRESSION OF EPSTEIN BARR VIRUS (EBV) GENES IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLPDs). (1999) (0)
Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy (2008) (0)
Depletion of NUP98: A Common Leukemogenetic Mechanism in AML? (2005) (0)
Genetic and Molecular Characterization of Novel Richter Syndrome Patient-Derived Xenograft Models (2017) (0)
Phase I /II T rial o f E pratuzumab ( Humanized A nti-CD22 Antibody) i n I ndolent N on-Hodgkin's L ymphoma (2003) (0)
Peroxisome Proliferator-Activated Receptor Gamma Promotes the Survival of Human T Lymphoma Cells through Its Regulation of Cellular Metabolism. (2006) (0)
of the JAK2 pathway Mechanisms of endothelial cell protection by blockade (2010) (0)
HAART-associated lymphadenopathy. (1999) (0)
Long‐Distance Tunneling Nanotubules Shuttle Immunoglobulin Class Switch‐Suppressing Factors from HIV‐Infected Macrophages to B Cells (2007) (0)
and in prenatal and postnatal thymus BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma (2000) (0)
Debunking the Myth That Hepatosplenic T-Cell Lymphoma Is Just a Disease of Young Males with Inflammatory Bowel Disease on Thiopurines: 1763 (2016) (0)
A Machine Learning Model Incorporating Laboratory Blood Tests Discriminates Between SARS-CoV-2 and Influenza Infections at Emergency Department Visit (2021) (0)
Quantitative Assessment of DNA Editing Enzymes in B-Cell Lymphomas. (2007) (0)
Non-Destructive Post-Transplant Lymphoproliferative Disorder Shows Distinct Clinical Features with HHV-6 Reactivation in a Subset (2019) (0)
Classifi cation of Lymphoma (2011) (0)
KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS (KSHV) INFECTION IN PROGRESSIVE HIV-RELATED LYMPHADENOPATHY (HIV-LAP). (1998) (0)
Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant MCL Cells for Killing by Proteasome Inhibitor Bortezomib by Activating Cell Cycle-Coupled Apoptosis (2008) (0)
Primary Effusion Lymphoma/Extracavitary Effusion Lymphoma: A Virus-Associated Lymphoma (2012) (0)
Influence of Lifestyle Factors On Expression of Tumor-Related Microenvironment T-Cells and Impact On Survival of Follicular Lymphoma (FL). (2012) (0)
An Unusual Sonographic Manifestation of Lymphoma of the Breast (1999) (0)
Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas (2023) (0)
Frequency, Histologic, and Prognostic Significance of CD30 Expression in AIDS-associated Diffuse Large B-Cell Lymphoma (2021) (0)
Abstract PO-42: TBL1XR1 mutations drive extranodal lymphomagenesis by inducing a protumorigenic memory B-cell fate (2020) (0)
Large Cell Lymphoma (2007) (0)
ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom (2012) (0)
ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia. (2009) (0)
Splenic SUV on FDG-PET in NHL correlates with histopathology findings at splenectomy (2007) (0)
Potential Use of Jak2 Inhibitors to Limit Ineffective Erythropoiesis and Reverse Splenomegaly in β-Thalassemia. (2008) (0)
Rapid Communication Hairy Cell Leukemia-Associated Antigen LeuM5 (CDi 1 c) Is Preferentially Expressed by Benign Activated and Neoplastic CD8 T Cells (2007) (0)
Building the Model. (2022) (0)
Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) (2012) (0)
The genetic landscape of immune-competent and HIV lymphoma (2012) (0)
Mutually Exclusive Structural Alterations of BLIMP1 and BCL6 Contribute to the Pathogenesis of Activated B Cell Type Diffuse Large B Cell Lymphoma. (2009) (0)
Classification of B-Cell Lymphomas and Immunodeficiency-Related Lymphoproliferations: What’s New? (2023) (0)
Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma (2022) (0)
HIV-1 induces targeted down-regulation of the Ig gene-diversifying enzyme AID in the germinal center of infected lymphoid follicles (45.1) (2007) (0)
Marginal Zone Lymphoma, Immune Dysregulation, and High-Grade Transformation (2019) (0)
MicroRNA-Mediated Down-Regulation of the Tumor Suppressor Gene PRDM1 /Blimp-1 in Diffuse Large B-Cell Lymphomas. (2007) (0)
Special Report International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease (2019) (0)
Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib. (2023) (0)
A comprehensive identification of the microrna transcriptome and its application in B cell malignancies (2009) (0)
CD33 Antigen Detection by PWS44 (2009) (0)
Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa (2017) (0)
Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients (2013) (0)
P115: Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma (2022) (0)
TNFAIP3(A20) genetic alterations in AIDS-related lymphomas (2010) (0)
This information is current as APRIL the TNF Family Members BAFF / BLyS and Lymphoma B Cells Evade Apoptosis through (2004) (0)
Metagenomic analysis to identify novel infectious agents in systemic anaplastic large cell lymphoma (2021) (0)
erythropoiesis in Decreased differentiation of erythroid cells exacerbates ineffective (2008) (0)
KSHV/HHV-8 INTERLEUKIN-6 (vIL6) EXPRESSION IN HIV-RELATED LYMPHADENOPATHY CORRELATES WITH DEVELOPMENT OF KAPOSI'S SARCOMA AND SURVIVAL. (1999) (0)
Distinct Laboratory Test Result Profiles Between SARS-CoV-2 and Seasonable Influenza Infected Patients. (2022) (0)
Value of FDG-PET in Prediction of Splenectomy Findings in Patients with Suspected or Known Lymphoma. (2006) (0)
DNA Polymerase Gene Expression in B-Cell Non-Hodgkin's Lymphomas (2002) (0)
Mucosal Epithelial Cells Initiate Frontline Immunoglobulin Class Switching through an SLPI-Regulated Pathway. (2006) (0)
Subject Index Vol. 118, 2007 (2007) (0)
USCAP 2018 Abstracts: Breast Pathology (121–337) (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Amy Chadburn?

Amy Chadburn is affiliated with the following schools:

Amy Chadburn's Academic­Influence.com Rankings

Amy Chadburn's Degrees

Similar Degrees You Can Earn

Why Is Amy Chadburn Influential?

Amy Chadburn's Published Works

Published Works

What Schools Are Affiliated With Amy Chadburn?

Amy Chadburn's AcademicInfluence.com Rankings